Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 255 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asymptomatic Condition Clear all
Completed Phase 2 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 6:13 PM EDT
Terminated Phase 1 Interventional

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

NCT02784483
View directory record Official record
Conditions
Asymptomatic Myeloma
Interventions
Atezolizumab (1200mg via IV infusion)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 30, 2026, 6:13 PM EDT
Recruiting Not applicable Interventional

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

NCT07539597
View directory record Official record
Conditions
Asymptomatic Hypertension
Interventions
Community Health Worker engagement
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Simulation Study of a Test Material on the Anterior Nares

NCT05617729
View directory record Official record
Conditions
Colonization, Asymptomatic
Interventions
Saline applied via swab, Povidone-iodine based gel
Other
Lead sponsor
Center for Innovation and Research Organization
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 30, 2026, 6:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the ID NOW™ CT/NG Test

NCT06395675
View directory record Official record
Conditions
Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Asymptomatic Condition
Interventions
ID NOW™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years and older
Enrollment
7,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 30, 2026, 6:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis

NCT01599195
View directory record Official record
Conditions
Carotid Stenosis, Femoral Arterial Stenosis, Carotid Bruit Asymptomatic, Carotid Murmur
Interventions
AudioDoc
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
19 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

NCT00002373
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Maribavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional

STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

NCT03988309
View directory record Official record
Conditions
Hematuria, Urothelial Carcinoma
Interventions
Cxbladder
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Winter Garden, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional

ECG AI-Guided Screening for Low Ejection Fraction

NCT04000087
View directory record Official record
Conditions
Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
Interventions
AI-enabled ECG-based Screening Tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 30, 2026, 6:13 PM EDT
Terminated Phase 1 Interventional

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

NCT02598427
View directory record Official record
Conditions
HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Kimberly Blackwell
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 30, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional Results available

Pembro+Chemo in Brain Mets

NCT04964960
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
Interventions
Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

NCT00000699
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer

NCT00508144
View directory record Official record
Conditions
Lung Cancer
Interventions
Alimta
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

NCT02008357
View directory record Official record
Conditions
Cognition Disorders
Interventions
Placebo, Solanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years to 85 Years
Enrollment
1,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 6:13 PM EDT
Terminated No phase listed Observational Results available

Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm

NCT01902888
View directory record Official record
Conditions
Popliteal Artery Aneurysm
Interventions
GORE® VIABAHN® Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Miami, Florida • Naples, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 3 Interventional

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

NCT00032344
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 30, 2026, 6:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

NCT05534321
View directory record Official record
Conditions
Spine Metastases
Interventions
Prophylactic Radiotherapy, Standard of care systemic therapy
Radiation · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional

An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT00002260
View directory record Official record
Conditions
HIV Infections
Interventions
Alovudine
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

NCT03316131
View directory record Official record
Conditions
Asymptomatic Hyperuricemia
Interventions
Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

NCT02089217
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Procedure · Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 100 Years
Enrollment
2,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
154
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 6:13 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT05640193
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel (LN-144)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 6:13 PM EDT